

CURRICULUM VITAE



Name. Mark Emmanuel Cooper
Date of Birth: 8th September 1956
Marital Status: Married
Phone No: Work: 8532 1362
Home: 8532 1362
Fax: 8532 1480
Email: mark.cooper@baker.edu.au
Address: 60 Chatsworth Rd East Prahran 3181

Education:

1961-1973 Mount Scopus College
1973 HSC: 7 A's, Top of the State of Victoria
General Exhibition.
Special Exhibitions: General Mathematics, Chemistry
1974-1979 University of Melbourne
1974 Medical Studies 1 H2
Physics H2
Chemistry H1
Biology H2
1976 Anatomy H3
Biochemistry H2
Physiology H3
Pathology H2
Pharmacology H3
Microbiology H3
Medical Studies 2 H2
1979 Medicine H3
Obstetrics & Gyn H3

Appointments:

1980 Intern, Austin Hospital
1981 J.R.M.O. (Medical), Austin Hospital
1982 S.R.M.O. (Medical), Austin Hospital
1983 Medical Registrar, Austin Hospital
F.R.A.C.P. - (Part 1)
1984 Endocrine Fellow, Austin Hospital
1985 Commencement of PhD, Melbourne University
1985- Assistant Physician, Endocrine Clinic, Austin Hospital
1985-87 National Heart Foundation Postgraduate Medical Scholarship
1986 Young Investigator Award - Australian Diabetes Society.
1986 F.R.A.C.P. awarded.

1984-88 Clinical Instructor, University of Melbourne
1987-88 Clinical Fellow, Austin Hospital
1988- Senior Research Officer, NH&MRC
Endocrinologist, Repatriation General Hospital, Heidelberg
1989 PhD awarded: "Diabetes and Hypertension -
Clinical and Experimental Aspects"
1991 Senior Lecturer, Department of Medicine,
Austin /Repatriation General Hospitals, University of Melbourne
1996 Associate Professor, Department of Medicine,
Austin & Repatriation Medical Centre (Repatriation Campus)
University of Melbourne
1999 Adjunct Associate Professor of Physiology, University of Melbourne
1999 Eric Susman Prize, Royal Australasian College of Physicians
2000-2002 Professor of Medicine, University of Melbourne
2001- Adjunct Professor of Physiology, University of Melbourne
2002- Senior Principal Research Fellow, Baker Medical Research Institute
2002- Honorary Professor of Medicine, University of Melbourne
2002- Professor of Medicine, Monash University
2003 Head, Vascular division, Baker Medical Research Institute
2003 Director, JDRF Danielle Alberti Memorial Centre for Diabetes
Complications

PUBLICATIONS

1. Thomas AK, Slobodniuk R, Taft J, Cooper M, Montalto J and Jerums G. The treatment of hirsutism: experience with cyproterone acetate and spironolactone. *Aust J.Derm* 26,19-24, 1985.
2. Jerums G, Cooper M and Goodall I. Is glycosylated haemoglobin useful for routine management of diabetes. *Hospital Practice* 1, 5-9, 1985.
3. Cooper ME, Duff R, Buchanan R, McPherson J and Jerums G. Low C4 concentrations are not associated with microangiopathy in type 1 and type 11 diabetes. *Brit Med J* 292, 801, 1986.
4. Cooper ME, Sia STB., Austin MC, McKay WJ., Jerums G and Douglas MC. Nuclear scanning in the diagnosis and localisation of parathyroid adenomas. *Medical Journal of Australia* 144, 521-524, 1986.
5. Cooper ME, Allen TJ., Jerums G.and Doyle AE. Accelerated progression of diabetic nephropathy in the spontaneous hypertensive streptozotocin diabetic rat. *Clin Exp.Pharmacol Physiol.* 13, 655-662, 1986.
6. Cooper ME, Goodman D, Frauman A, Jerums G and Louis WJ. Pheochromocytoma in the elderly - a poorly recognised entity. *Brit Med J.*293, 1474-1475, 1986.
7. Jerums G, Murray RML, Seeman E, Cooper M, Edgley S, Markwick K, Larkins RG. and Martin TJ. Lack of effect of gliclazide on early diabetic nephropathy and retinopathy: a two year controlled study. *Diabetes Research and Clinical Practice* 3, 71-80, 1987.
8. Cooper ME., Murray RML Kalnins R, Woodward J and Jerums G.. The development of Cushing's Syndrome from a previously silent pituitary tumour *Aust NZ J Med.*17, 249-251, 1987.
9. Jerums G, Cooper M, Seeman E, Murray RML. and McNeill JJ. The spectrum of proteinuria in type 1 and type 11 diabetes. *Diabetes Care* 10, 419-427, 1987.
10. Frauman A, Cooper ME., Parsons BJ., Jerums G. and Louis W. Long-term use of intra-nasal insulin in insulin-dependent diabetics. *Diabetes Care* 10, 573-578, 1987.
11. Cooper ME., Seeman E, Murray RML, Favilla ML. and Jerums G. Time course of progression of proteinuria in type 1 and type 11 diabetes. in: "Microvascular and Neurological Complication of Diabetes". Eds. G. Crepaldi, JC. Cunha Vaz, CE. Mogensen, JD. Ward and D Fedele. *Fidia Research Series Vol.10 Section 11* 191-197 Liviana Press, Padova, 1987.
12. Jerums G, Cooper ME., Seeman E, Murray RML, McNeil J Comparison of Early renal dysfunction in type 1 and type 11 diabetes: Differing associations with Blood Pressure and Glycaemic Control. *Diabetic Research and Clinical Practice* 4, 133-141, 1988.
13. Cooper ME.,Allen TJ. Macmillan P, Bach L, Jerums G and Doyle AE. Genetic hypertension accelerates nephropathy in the Streptozotocin Diabetic Rat. *Am J Hypertension* 1, 5-10, 1988.
14. Cooper ME., Frauman A, O'Brien RC., Seeman E, Murray RML. and Jerums G. Progression of Proteinuria in Type 1 and Type 11 Diabetics. *Diabetic Medicine* 5, 361-368, 1988.
15. O'Brien RC., Allen TJ., Cooper ME., Bach L and Jerums G. Glomerular Filtration Rate in Early Experimental Diabetes. *J Diabetic Complications* 2, 8-11, 1988.
16. Jackson B, Franze L, Allen TJ., O'Brien R, Cooper M, Hodsman PG and Jerums G. Effect of glycaemic control on hyperfiltration, salt and volume status in the Streptozotocin Diabetic Rat. *Clin Exp Pharmacol Physiol*, 15, 361-365, 1988.

17. Murray R, Dowsett M, Cooper ME., Allen TJ., Lawson P, Story H and Syme R. Effects of Aromatase Inhibition with Aminoglutethimide in Men with Benign Prostatic Hypertrophy *in: Steroids* 50, 4-6, pp 647-648, Bradlow HL, Ed Butterworths, London, 1988.
18. Seeman E, Cooper ME., Hopper J, Parkinson E, McKay J and Jerums G. The effect of Early Menopause on Bone Mass in Normal Women and Patients with osteoporosis. *Am J Med* 85, 213-216, 1988.
19. Cooper ME., Allen TJ., Macmillan PA., O'Brien RC., Clarke B, Jerums G. and Doyle AE. Effects of genetic hypertension on Diabetic Nephropathy in the Rat - functional and structural characteristics. *J Hypertension* 6, 1009-1016, 1988.
20. Cooper ME., O'Brien RC., Murray RML, Seeman E. and Jerums G. Role of protein intake, blood pressure and glycaemic control in transient microproteinuria in type 1 and type 11 diabetes. *J Diab Comp* 3, 92-98, 1989.
21. O'Brien RC, Cooper ME, Allen TJ and Jerums G. Ramipril reduces proteinuria in diabetic rats fed a high protein diet. *Clin Exp Pharmacol Physiol.* 16: 675 - 680, 1989.
22. Allen TJ., Macmillan P, Cooper ME, O'Brien RC, and Jerums G. Atrial Natriuretic Peptide Activity, Exchangeable Sodium and Glomerular Filtration Rate in Experimental Diabetes. *Proc. 3rd International Symposium on Diabetes Mellitus. Excerpta Medica Intl. Series, Elsevier Science Publishers B.V., Biomedical Division Current Status of prevention and treatment of diabetic complications. N. Sakamoto, K.G.M.M. Alberti and N. Hotta, eds. pp 520-525, 1990.*
23. Soulis T, Cooper M. Layton G, Allen T and Jerums G. Aminoguanidine reduces tissue fluorescence but not albuminuria in experimental diabetes. "Glycated Proteins in Diabetes Mellitus" Ed: RG Ryall. pp 310-320, University of Adelaide printing 1990.
24. Jerums G, Wirth A, Tsalamandris C, Allen T, O'Brien R, Bach L and Cooper M. Determinants of progression of diabetic nephropathy. In "Diabetes 1988" Eds. R.Larkins, P.Zimmet, D.Chisholm. Elsevier Science Publishers BV 527-530, 1989.
25. Cooper M, Allen TJ and Macmillan P. Interaction of Diabetes and Hypertension in Experimental Diabetes. In "Diabetes 1988". Eds. R.Larkins, P.Zimmet, D Chisholm. Elsevier Science Publishers BV 467-470, 1989.
26. Seeman E, Miach PJ., Cooper M and Dawborn JK. Bone Mass following Transplantation. *Transplant Proc* 21, 2159-2160, 1989.
27. Seeman E, Hopper JL, Bach LA, Cooper ME, Parkinson E, McKay J and Jerums G. Bone Mass in Daughters of Women with Osteoporosis *N Engl J Med* 320, 554-558, 1989.
28. Cooper ME, Allen TJ., Macmillan PA. Clarke BA., Jerums G and Doyle AE. Enalapril retards albuminuria and glomerular basement membrane thickening in experimental diabetic nephropathy. *Diabetologia* 32, 326-328, 1989.
29. Jerums G. Allen TJ. and Cooper ME. Triphasic changes in selectivity with increasing proteinuria in type I and type II Diabetes. *Diabetic Medicine* 6: 772-779, 1989.
30. Bach LA, Cooper ME, O'Brien RC, Jerums G. The use of Simvastatin, an HMG CoA reductase inhibitor in elderly patients with hypercholesterolaemia. *J Am Ger Soc* 38, 10-14, 1990.

31. Cooper ME, Vranes DA, Panagiotopoulos S, Allen TJ, Goodall I and Jerums G. Hyperlipidaemia increases albuminuria in hypertensive and normotensive rats. *Clin Exp Pharm Physiol* 17, 225-228, 1990.
32. O'Brien RC, Simons LA, Clifton P, Cooper ME, Jennings GL, Jerums G, Nestel PJ and Sullivan D. Comparison of simvastatin and cholestyramine in the treatment of primary hypercholesterolaemia. *Med J Aust* 152, 480-483, 1990.
33. Allen TJ, Cooper ME, O'Brien RC, Bach LA, Jackson B, Jerums G. Glomerular filtration rate in the streptozocin diabetic rat: The role of exchangeable sodium, vasoactive hormones and insulin therapy. *Diabetes* 38, 1182-1190, 1990.
34. Cooper ME, Allen TJ, O'Brien RC, Papazoglou D, Clarke B, Jerums G and Doyle AE. Nephropathy in a Model Combining Genetic Hypertension with Experimental Diabetes: Enalapril versus Hydralazine and Metoprolol Therapy. *Diabetes* 39, 1575-9, 1990.
35. Allen TJ, Cooper M, Jerums G, DeLuise M, Alford F, Doyle A, Hammond J, Mashford L, McMenamin C, Mohr M, Raffaele J, Westwood B. Melbourne Diabetic Nephropathy Study Group. Comparison of the effects between perindopril and nifedipine in hypertensive and normotensive diabetic patients with microalbuminuria. *Brit Med J* 302, 210-216, 1991.
36. O'Brien RC, Cooper ME, Murray RML, Seeman E, Thomas AK, Jerums G. Comparison of spironolactone and cyproterone acetate in the treatment of hirsutism. *J Clin Endo Metab* 72, 1008-1013, 1991.
37. Chang WP, Dimitriadis E, Allen T, Dunlop ME, Cooper ME, Larkins RG. The effect of aldose reductase inhibition on glomerular prostaglandin production and urinary albumin excretion in experimental diabetes. *Diabetologia* 34, 225-231, 1991.
38. Bach LA, Wirth A, O'Brien RC, Jerums G, Cooper ME. Cholesterol lowering effects of simvastatin in patients with diabetes mellitus. *Diabetes, Nutrition and Metabolism* 4, 123-128, 1991.
39. Soulis-Liparota T, Cooper M, Papazoglou D, Clarke B, Jerums G. Aminoguanidine retards the development of albuminuria, mesangial expansion and tissue fluorescence in the streptozocin-induced diabetic rat. *Diabetes* 40: 1328-34, 1991.
40. Gilbert R and Cooper ME. Hypertension in the type II diabetic patient: implications and therapeutic intervention. *Treating Diabetes* No. 5, 1991.
41. Jerums G, Allen T, Tsalamandris C, Cooper ME and the Melbourne Diabetic Nephropathy Group. Angiotensin Enzyme inhibition and Calcium channel blockade in incipient diabetic nephropathy. *Kidney Int*, 41, 904-911, 1992.
42. Cooper ME, O'Brien RC, Allen TJ, Jerums G and Doyle AE. Antihypertensive therapy in a model combining spontaneous hypertension with diabetes. *Kidney Int*, 41, 898-903, 1992.
43. Cooper ME. The role of hypertension in the development of renal disease. *Medicographia*, 13(3), 29-32, 1991.
44. Jerums G, Tsalamandris C, Bach LA, Gilbert RE, Allen TJ, Cooper ME, Panagiotopoulos S and O'Brien RC. The natural history of diabetic nephropathy in: Rifkin H, Colwell JA, Taylor SI (eds) Diabetes 1991, Elsevier Science Publishers BV, 649-654, 1991.
45. Cooper ME, Rumble JR, O'Brien RC, Allen TJ, Jerums G and Doyle AE. Nephropathy in the diabetic SHR: The effects of perindopril and triple therapy. *Genetic Hypertension* 218, 381-383, 1992.

46. Jandeleit K, Rumble J, Jackson B and Cooper ME. Mesenteric Vascular Angiotensin Converting Enzyme is increased in experimental diabetes mellitus. *Clin Exp Pharmacol Physiol* 19, 343-347, 1992.
47. Johnston CI, Cooper ME and Nicholls G. Meeting Report of the International Society of Hypertension Conference on Hypertension and Diabetes. *J Hypertens* 10, 393-397, 1992.
48. Cooper ME and Doyle AE. The management of diabetic proteinuria: which antihypertensive agent? *Drugs and Aging*, 2, 301-309, 1992.
49. Cooper ME, Rumble JR, Gin T and Lim-Joon T. Diabetic renal microvascular disease: The role of hypertension and ACE inhibitors. *Clin Exp Pharm Physiol* 19, (Suppl 19) 23-27, 1992.
50. Cooper ME and Doyle AE. The management of diabetic proteinuria: which antihypertensive agent? *Current Therapeutics* Nov 92, 41-43.
51. Cooper ME. Recent Advances in Endocrinology and Diabetes. *Fellowship Affairs* 12, 23, 1993.
52. O'Brien RC, Cooper ME, Jerums G and Doyle AE. The effects of perindopril and triple therapy in a normotensive model of diabetic nephropathy. *Diabetes*, 42, 604-609, 1993.
53. Jerums G, Allen TJ, Tsalamandris C, Akdeniz A, Sinha A, Gilbert R and Cooper ME. Relationship of progressively increasing proteinuria to apoprotein (a) and blood pressure in type II and type I diabetic patients. *Diabetologia* 36, 1037-1044, 1993.
54. Cooper ME, Sinha AK and O'Brien RC. Lipid disorders in the diabetic patient. *Proc 3rd Annual ASEANZ Lipid Forum: Current issues Excerpta Medica* 16-21, 1993.
55. Gilbert R, Tsalamandris C, Bach LA, Panagiotopoulos S, O'Brien RC, Allen TJ, Goodall I, Young V, Seeman E, Murray RML, Cooper ME and Jerums G. Longterm glycemic control and the rate of progression of early diabetic kidney disease. *Kidney Inter* 44, 855-859, 1993.
56. Cooper ME and Sinha AK. Why diagnose dyslipidaemias? *Heartbeat* 7 9-11, 1993.
57. Cooper ME, Doyle AE. Managing diabetic proteinuria: which antihypertensive agent? *Current Therapeutics* 33(11):41-43, 1992.
58. Cooper ME and Doyle AE. Managing diabetic proteinuria. *New Ethicals* 30(6):81-85, 1993.
59. Cooper ME, Sinha A. Case histories in "Clinicians Handbook on Lipids". ADIS press 1994.
60. Cooper ME. What are the appropriate indications for use of an ACE inhibitor vs a calcium antagonist in a patient with diabetic nephropathy. *Current Therapeutics* Jan 1994, 26-27.
61. Cooper ME. What are the appropriate indications for use of an ACE inhibitor vs a calcium antagonist in a patient with diabetic nephropathy. *New Ethicals* 30 (11), 42-43, 1993.
62. Bach LA, Gilbert RE, Cooper ME, Tsalamandris C and Jerums G. Prediction of persistent microalbuminuria in patients with diabetes mellitus. *J Diab Compl* 7, 67-72, 1993.
63. Tsalamandris C, Allen T, Gilbert RG, Sinha A, Panagiotopoulos S, Cooper ME and Jerums G. Progressive decline in renal function in diabetic patients with and without albuminuria. *Diabetes* 43, 649-655, 1994.

64. Cooper ME and Sinha A. Treating dyslipidaemia in general practice. *Sigma Clinical Series* 21, 1994.
65. Johnston CIJ and Cooper ME. ACE inhibitors in diabetic patients. In: *ACE Inhibition, Hypertension and Related Diseases*. Media Medica Publications pp73-81, 1993.
66. Cooper ME, Vranes D, Vranes DA, Allen TJ, Panagiotopoulos S, Komers R, Jerums G. The effects of dietary cholesterol on experimental diabetic nephropathy. *Diabetes Research* 22, 159-69, 1993.
67. Komers R, Allen TJ Cooper ME. Role of endothelium-derived nitric oxide in the pathogenesis of the renal hemodynamic changes of experimental diabetes. *Diabetes* 43, 1190-97, 1994.
68. Cooper ME, Rumble J, Komers R, Du H-C, Jandeleit K and Chou ST. Diabetes associated mesenteric vascular hypertrophy is attenuated by angiotensin converting enzyme inhibition. *Diabetes* 43, 1221-1228, 1994.
69. Trinder D, Phillips PA, Stephenson JM, Risvanis J, Aminian A, Adam W, Cooper M, Johnston CI. Vasopressin V1 and V2 receptors in diabetes mellitus. *Am J Physiol* 266: E217-E223, 1994.
70. McNally PJ and Cooper ME. Antihypertensive treatment in NIDDM, with special reference to abnormal albuminuria. In "The kidney and hypertension in diabetes mellitus". Ed. CE Mogensen, Kluwer Academi Publishers , Norwell, Mass USA 1994, Chapter 32, pp341-352.
71. Doyle AE, Jerums G and Cooper ME. Can diabetic nephropathy be delayed or prevented? in: *Inhibition of the Renin Angiotensin System: Recent Advances*. Eds. MacGregor GA and Sever PS. (in press, 1994).
72. Jerums G, Soulis-Liparota T, Panagiotopoulos S, Cooper ME. In vivo effects of aminoguanidine. in: *Maillard Reactions in Chemistry, Food and Health*. Eds: Labuza TP, Reineccius GA, Monnier V, O'Brien J, Baynes J. Royal Society of Chemistry, pp319-323, 1994.
73. Tsalamandris C, Panagiotopoulos S, Sinha A, Cooper ME and Jerums G. Complementary effects of pravastatin and nicotinic acid in the treatment of combined hyperlipidaemia in diabetic and non-diabetic patients. *J Cardiovascular Risk* 1, 231-239, 1994.
74. Gilbert R, Cooper ME, McNally PG, O'Brien RC, Taft J and Jerums G. Microalbuminuria: Prognostic and Therapeutic Implications in Diabetes Mellitus. *Diabetic Medicine* 11, 636-645, 1994.
75. Jerums G, Cooper M, Gilbert R, O'Brien R and Taft J. Microalbuminuria in Diabetes. *Med J Aust* 161, 265-268, 1994.
76. Rumble JR, Doyle AE and Cooper ME. Comparison of effects of ACE inhibition with calcium channel blockade on renal disease in a model combining genetic hypertension with diabetes. *Am J Hypertens* 8, 53-57, 1995.
77. Soulis-Liparota T, Cooper ME, Dunlop M, Jerums G. The relative roles of advanced glycation, oxidation and aldose reductase inhibition in the development of experimental diabetic nephropathy. *Diabetologia* 38, 387-394, 1995.
78. Komers R and Cooper ME. Acute renal haemodynamic effects of angiotensin converting enzyme inhibition in diabetic hyperfiltration: The role of kinins. *Am J Physiol* 268, F588-F594, 1995.
79. Cooper ME. Hypertension and the kidney. in *Current Concepts in Hypertension* Eds GS Sainani. pp54-63. Indian College of Physicians 1995.

80. Watts GF , Jasik M and Cooper ME. The implications of the detection of proteinuria and microalbuminuria in insulin and non-insulin dependent diabetes. *Aust NZ J Med* 25, 157-161, 1995
81. Bach LA, Cooper ME, Vranes D, Allen TJ, Rumble J and Jerums G. Disparate effects of castration on renal structure and function in the streptozotocin diabetic rat. *Diabetes Research* 27: 27-38, 1994..
82. Jerums G, Soulis T, Panagiotopoulos S, Cooper ME. In Vivo Effects of Aminoguanidine in Experimental Diabetes and Atherosclerosis. *Diabetes* 1994. Elsevier Science BV International Congress Series No 1100 299-305, 1995.
83. Jerums G, Allen T, Gilbert R, Hammond J, Cooper ME, Campbell DJC, Raffaele J and the Melbourne Diabetic Nephropathy Study Group. Natural History of Early Diabetic Nephropathy: What are the effects of therapeutic intervention? *J Diab Compl* 9, 308-314, 1995.
84. Allen TJ, Hulthen UL, Rumble J, Jasik M and Cooper ME. Diabetic Vascular Hypertrophy and Albuminuria : Role of ACE Inhibition. *J Diab Compl* 9, 318-322, 1995.
85. Cooper ME and Komers R. Renal haemodynamic changes in diabetes. *Diabetes* 1994. Elsevier Science BV International Congress Series No 1100 355-360, 1995.
86. Jerums G, Allen TJ, Gilbert R, Panagiotopoulos S, Tsalamandris C, Hendrich EC and Cooper ME. Natural History of Diabetic Nephropathy. *Diabetes* 1994. Elsevier Science BV International Congress Series No 1100 695-700, 1995.
87. Vranes D, Dilley RJ and Cooper ME. Vascular changes in the diabetic kidney: Effects of ACE Inhibition. *J Diab Compl* 9, 296-300, 1995.
88. Gilbert RE, Cox A, Cooper ME and Jerums G. Extracellular Matrix and its interactions in the diabetic kidney: A Molecular Biological Approach. *J Diab Compl* 9, 252-254, 1995.
89. Vranes D, Cooper ME and Dilley RJ. Angiotensin Converting Enzyme inhibition reduces diabetes-induced vascular hypertrophy: morphometric studies. *J Vasc Res* 32: 183-189, 1995.
90. Hulthen UL, Rumble J, Cooper ME and Johnston CI. Vascular albumin permeability and hypertrophy in a rat model combining streptozotocin-induced diabetes and genetic hypertension. *J Hypertension* 13, 529-33, 1995.
91. Gilbert R, McNally PG, Cox A, Dziadek M, Rumble J, Cooper ME and Jerums G. Gene expression of the anti-adhesive extracellular matrix protein secreted protein acidic and rich in cysteine (SPARC) is reduced in early diabetes related growth. *Kidney Inter* 48, 1216-25, 1995.
92. Haynes JM and Cooper ME. Adrenomedullin and calcitonin gene-related peptide in the rat isolated kidney and in the anaesthetised rat: a comparison of in vitro and in vivo effects. *Eur J Pharmacol* 280, 91-94, 1995.
93. Gin T, Joon T, Panagiotopoulos S, Cooper M, Taylor H, Jerums G. Organ specificity of antihypertensive therapy on ocular albumin clearance and albuminuria in the hypertensive diabetic rat. *Invest Ophthalmol Vis Sci* 37, 281-289, 1996.
94. Cooper ME, McNally PG, Phillips PA, Johnston CI. Amylin Stimulates Plasma Renin Concentration in Man: Implications for the Association of Hypertension With Insulin Resistance? *Hypertension* 26: 460-464, 1995.
95. Hardy KJ, Akdeniz A and Cooper ME. Effects of liver resection and transplantation on lipid parameters. *European IHPBA Congress Athens 95*. Ed: L Papastamatiou. Monduzzi Editore 949-953, 1995.

96. Cooper ME. Microalbuminuria. *Current Therapeutics - Diabetes* 2, 16-18, 1995.
97. Gilbert R, Jerums G and Cooper ME. Diabetes and hypertension: prognostic and therapeutic considerations. *Blood Pressure* 4, 329-338, 1995.
98. Gilbert RE, Jasik M, DeLuise M, O'Callaghan C and Cooper ME. Diabetes and Hypertension. Australian Diabetes Society Position statement. *Med J Aust* 163, 372-375, 1995.
99. Wookey PJ, Tikellis C, Du H-C, Qin H-F, Sexton PM and Cooper ME. Amylin binding in rat renal cortex, stimulation of adenylyl cyclase and activation of plasma renin. *Am J Physiol* 270: F289-F294, 1996.
100. Cooper ME, Vranes D and Rumble JR. Diabetic vascular injury and ACE: Potential for Pharmacological Prevention of Complications of Later Life. *Drugs and Aging* 8, 38-46, 1996.
101. Cooper ME and McNally PJ. Antihypertensive treatment in NIDDM, with special reference to abnormal albuminuria. In "The kidney and hypertension in diabetes mellitus". 3rd Edition. Ed. CE Mogensen, Kluwer Academi Publishers, Norwell, Mass USA pp385-395, 1997.
102. Rumble JR, Komers R and Cooper ME. Kinins/nitric oxide are involved in the anti-trophic effects of ACE inhibitors on diabetes associated mesenteric vascular hypertrophy. *J Hypertension* 14, 601-607, 1996.
103. Gilbert RE, Cooper ME and Jerums G. Primary prevention of stroke. *N Engl J Med* 334, 1138-1139, 1996
104. Soulis T, Cooper ME, Vranes D, Bucala R, Jerums G. The effects of aminoguanidine in preventing experimental diabetic nephropathy are related to duration of treatment. *Kidney Inter* 50, 627-634, 1996.
105. Hulthen UL, Cao Z, Rumble JR, Cooper ME and Johnston CI. Vascular hypertrophy and albumin permeability in a rat model combining hypertension and diabetes: effects of calcium antagonism, ACE inhibition and AII-AT1 receptor blockade. *Am J Hypertens* 9, 895-901, 1996.
106. Allen TJ, Cooper ME, Gilbert RE, Winikoff J, Skinner SL, Jerums G. Plasma Total Renin is Increased Before Microalbuminuria In Diabetes (IDDM). *Kidney Inter* 50: 902-907, 1996.
107. Cooper ME and Soulis T. Advanced glycation end products. in *The Clinical Biochemist: Diabetes, glycation and other complications*. Excelsior Printing works, Box Hill, Australia, May 1996, pp61-.
108. Cooper ME. Renal Protection And ACE Inhibition In Microalbuminuric Type I And Type II Diabetic Patients. *J Hypertens* 14, Suppl 6, S11-S14, 1996.
109. Komers R and Cooper ME. Renal sodium handling in experimental diabetes: Role of NO. *Nephrol Dial Transpl* 11, 2170-77, 1996
110. Cooper ME, Akdeniz A and Hardy KJ. Effects of liver resection and transplantation on lipid parameters: a longitudinal study. *ANZ J Surgery* 66, 751-54, 1996.
111. Gilbert RE, Cooper ME and Jerums G. Extracellular matrix, growth factors and their interactions in the pathogenesis of diabetic kidney disease. *Nephrology* 2, 291-303, 1996.
112. Harris PJ, Cooper ME, Hiranyachattada S, Berka JL, Kelly DJ, Nobes M and Wookey PJ. Amylin stimulates proximal tubular sodium transport and cell proliferation in the rat kidney. *Am J Physiol* 272, F13-F21, 1997.

113. Allen TJ, Waldron MJ, Casley D, Jerums G and Cooper ME. Salt restriction reduces hyperfiltration, renal enlargement and albuminuria in experimental diabetes. *Diabetes* 46, 119-124, 1997.
114. Cooper ME and Wookey PJ. Amylin-its role in the kidney. *Nephrol Dial Transpl* 12, 8-10, 1997.
115. Haynes J, Hodgson W and Cooper ME. Rat amylin mediates a pressor effect in the anaesthetised rat. *Diabetologia* 40, 256-261, 1997.
116. Cooper ME. Antihypertensive therapy and diabetic microvascular disease. *Clin Exp Hyper* 19, 769-778, 1997
117. Wu L, Roe C, Cox A, Dziadek M, Cooper ME and Gilbert RE. Transforming growth factor β 1 and renal injury following subtotal nephrectomy in the rat: Role of the renin-angiotensin system. *Kidney Inter* 51, 1553-1567, 1997.
118. Rumble JR, Cooper ME, Soulis T, Cox A, Wu L, Youssef S, Jasik M, Jerums G, Gilbert RE. Vascular hypertrophy in experimental diabetes: role of advanced glycation end products. *J Clin Invest* 99, 1016-1027, 1997.
119. Wookey PJ, Cao Z, van Geenen RCI, Voskuil M, Darby IA, Komers R and Cooper ME. Increased density of renal amylin binding sites in experimental hypertension. *Hypertension* 30, 455-460, 1997.
120. Soulis T, Thallas V, Youssef S, Gilbert RE, McWilliam B, Murray-McIntosh RP, Cooper ME. Advanced glycation end products and the receptor for advanced glycated end products co-localise in organs susceptible to diabetic microvascular injury: immunohistochemical studies. *Diabetologia* 40, 619-628, 1997.
121. Gilbert RE, Cox A, McNally PG, Wu L, Dziadek M, Cooper ME and Jerums G. Increased Epidermal Growth Factor in Experimental Diabetes Related Kidney Growth. *Diabetologia* 40, 778-785, 1997
122. Cooper ME, Jerums G, Gilbert RE. Diabetic vascular complications. *Clin Exp Pharmacol Physiol* 24, 770-775, 1997.
123. Cooper ME. Mode of action of ACE inhibitors in diabetic nephropathy. *Medicographia* 19 (2), 108-112, 1997.
124. Cooper ME, Allen TJ and Couper J. Nephropathy and Hypertension in "Diabetes and the Adolescent". Eds: Werther G and Court J. Miranova Publishers (Melbourne, Australia). pp139-156, 1998.
125. Wu L, Cox A, Roe CJ, Dziadek M, Cooper ME and Gilbert RE. Secreted Protein Acidic and Rich in Cysteine Expression Following Subtotal Nephrectomy and Blockade of The Renin-Angiotensin System. *J Am Soc Nephrol* 8, 1373-1382, 1997
126. Allen TJ, Cao Z, Youssef S, Hulthen UL, Cooper ME. The role of angiotensin II and bradykinin in experimental diabetic nephropathy: functional and structural studies. *Diabetes* 46:1612-1618, 1997
127. Cooper ME, Cao Z, Rumble JR, Jandeleit K, Allen TJ, Gilbert RE. Attenuation of diabetes associated mesenteric vascular hypertrophy with perindopril: Morphological and molecular biological studies. *Metabolism* 12 Suppl 1, 24-27, 1998.
128. Roufail E, Soulis T, Cooper ME and Rees SM. Aminoguanidine treatment prevents the depletion of neurons containing nitric oxide synthase in the streptozotocin diabetic rat. In: *The Maillard reaction in foods and medicine*, pages 279-284, Edited by J O'Brien, HE Nursten, MJC Crabbe and JM Ames. Proceedings of the 6th International Symposium on the Maillard Reaction.

129. Soulis T, Cooper ME, Sastra S, Thallas V, Panagiotopoulos S, Bjerrum OJ, Jerums G. Relative Contributions Of Advanced Glycation And Nitric Oxide Synthase Inhibition To Aminoguanidine-Mediated Renoprotection In Diabetes. *Diabetologia* 40, 1141-51, 1997.
130. Cao Z, Wookey PJ, Wu L, Voskuil M, van Geenen RCI, Cooper ME. Rat amylin binding in normotensive and hypertensive rats: effects of angiotensin converting enzyme inhibition with perindopril. *J Hypertens* 15, 1245-1252, 1997
131. Wookey PJ, Tikellis C, Nobes M, Casley D, Cooper ME and Darby IA. Amylin as a growth factor during foetal and postnatal development of the kidney. *Kidney Int* 53, 25-30, 1998.
132. Epstein M and Cooper ME. Diabetic nephropathy: Focus on ACE inhibition and calcium channel blockade. in: *Calcium Antagonists in Clinical Medicine*. Ed. Epstein M. 2nd Edition. Hanley & Belfus Inc. Philadelphia USA pp.243-271, 1998.
133. Panagiotopoulos S, O'Brien RC, Bucala R, Cooper ME, Jerums G. Aminoguanidine has an anti-atherogenic effect in the cholesterol-fed rabbit. *Atherosclerosis* 136, 125-131, 1998.
134. Cooper ME, Gilbert RE and Epstein M. Pathophysiology Of Diabetic Nephropathy. *Metabolism Suppl* 1, 3-6, 1998.
135. Cooper ME and McNally PJ. Antihypertensive treatment in NIDDM, with special reference to abnormal albuminuria. In "The kidney and hypertension in diabetes mellitus". 4th Edition. Ed. CE Mogensen, Kluwer Academi Publishers, Norwell, Mass USA 427-440, 1998.
136. Cooper ME and Jerums G. Role of advanced glycation in diabetic nephropathy. In "The kidney and hypertension in diabetes mellitus". 4th Edition. Ed. CE Mogensen, Kluwer Academi Publishers, Norwell, Mass USA 265-270, 1998.
137. Cooper ME and Williams B. Addendum regarding renovascular hypertension and renal artery stenosis (especially NIDDM). In "The kidney and hypertension in diabetes mellitus". 4th Edition. Ed. CE Mogensen, Kluwer Academi Publishers, Norwell, Mass USA 440-441, 1998.
138. Chai SY, Christopoulos G, Cooper M and Sexton PM. Localisation and characterisation of renal binding sites for amylin, calcitonin and calcitonin gene-related peptide in primate kidney. *Am. J. Physiol.* 274, F51-62, 1998.
139. Wu LL, Yang N, Roe CJ, Cooper ME, Gilbert RE, Atkins RC and Lan HY. Macrophage and myofibroblast proliferation in remnant kidney: role of angiotensin II. *Kidney Inter* 52, Suppl 63, S221-S225, 1997.
140. Cao Z, Hulthén UL, Allen TJ, Cooper ME. Angiotensin Converting Enzyme Inhibition and Calcium Channel Blockade Attenuate Streptozotocin Diabetes-Associated Mesenteric Vascular Hypertrophy Independent of Their Hypotensive Action. *J Hypertens* 16: 793-799, 1998.
141. Cooper ME. Diabetic nephropathy: pathogenesis, prevention and treatment. *Lancet* 352, 213-219, 1998.
142. Gilbert RE, Cox A, Wu LL, Allen TJ, Hulthen L, Jerums G, Cooper ME. Expression of transforming growth factor- β 1 and type IV collagen in the renal tubulointerstitium in experimental diabetes: effects of angiotensin converting enzyme inhibition. *Diabetes* 47, 414-422, 1998.
143. Gilbert RE, Cooper ME and Krum H. Drug administration in patients with diabetes mellitus: safety considerations *Drug Safety* 18, 441-455, 1998

144. Kelly DJ, Wilkinson-Berka JL, Allen TJ, Cooper ME and Skinner SL. A new model of diabetic nephropathy with progressive renal impairment in the transgenic (mRen-2)27 rat. *Kidney Inter* 54: 343-352, 1998.
145. Wookey PJ and Cooper ME. Amylin: its physiological and pathophysiological roles in the kidney. *Clin Exp Pharmacol Physiol* 25, 653-660, 1998
146. Cooper ME. Advanced glycation end products and inhibitors. *Nephrol Dial Transpl* 13, 1069-1070, 1998.
147. Tikkanen T, Tikkanen I, Rockell M, Allen TJ, Johnston CI, Cooper ME and Burrell LM. Dual Inhibition of Neutral Endopeptidase and Angiotensin Converting Enzyme in Rats with Hypertension and Diabetes Mellitus. *Hypertension* 32, 778-785, 1998.
148. Gilbert RE, Berka J, Johnson DW, Cox A, Kelly DJ, Soulis T, Wu LL, Jerums G, Pollock CA, Cooper ME. Localization and gene expression of transforming growth factor- β inducible gene-h3 (β ig-h3) in control and diabetic rat kidneys. *Kidney Int* 54, 1052-1062, 1998
149. Gilbert RE, Vranes D, Berka JL, Kelly DJ, Cox A, Wu LL, Stacker SA and Cooper ME. Vascular Endothelial Growth Factor and its Receptors in Control and Diabetic Rat Eyes. *Lab Invest* 78:1017-1027, 1998
150. Yang N, Wu LL, Nikolic-Paterson DJ, Ng YY, Yang WC, Mu W, Gilbert RE, Cooper ME, Atkins RC, Lan HY. Local macrophage and myofibroblast proliferation in progressive renal injury in the rat remnant kidney.. *Nephrol Dial Transplant* 13:1967-1974, 1998
151. Yu HCM, Burrell LM, Black MJ, Wu LL, Dilley RJ, Cooper ME, Johnston CI. Salt Induces Myocardial And Renal Fibrosis In Normotensive And Hypertensive Rats. *Circulation* 98, 2621-2628, 1998
152. Rumble JR, Gilbert RE, Cox A, Wu L, Cooper ME. ACE inhibition reduces TGF- β 1 and type IV collagen expression in diabetic vasculopathy. *J Hypertens* 16, 1603-1609, 1998
153. Ruofail E, Soulis T, ME Cooper, Rees S. Depletion of nitric oxide synthase-containing neurons in the diabetic retina: reversal by aminoguanidine. *Diabetologia* 41, 1419-1425, 1998
154. Vranes D, Dilley RJ and Cooper ME. Vascular hypertrophy mechanisms in diabetes. *Microvasc Res* 57, 8-18, 1999
155. Cooper ME. Renoprotection with antihypertensive agents in normotensive diabetic subjects. *Diabetes Reviews International* 7(3), 12-15, 1998
156. Cooper ME, Gilbert RE, Kelly D, Allen TJ: Experimental Diabetic Nephropathy, in *Lessons from Animal diabetes VII*, edited by Sima A, , Elsevier, pp207-223, 1998.
157. Youssef S, Soulis T and Cooper ME. Hepatic advanced glycation endproduct binding is increased in experimental diabetes. *Cellular and Molecular Biology* 44, 1095-1100, 1998
158. Youssef S, Nguyen DT, Soulis T, Panagiotopoulos S, Jerums G and Cooper ME. Effect of diabetes and aminoguanidine therapy on renal advanced glycation endproduct binding. *Kidney Int* 55:907-916,1999
159. Soulis T, Sastra S, Thallas V, Mortensen SB, Wilken M, Clausen JT, Bjerrum OJ, Petersen H, Lau J, Jerums G, Boel E and Cooper ME. A novel inhibitor of advanced glycation end-product formation inhibits mesenteric vascular hypertrophy in experimental diabetes. *Diabetologia* 42, 472-479, 1999

160. Wookey PJ, Cao Z and Cooper ME. Interaction of the renal amylin and renin-angiotensin systems in animal models of diabetes and hypertension. *Mineral and Electrolyte Metabolism* 24, 389-399, 1998
161. Kelly DJ, Wilkinson-Berka JL, Cooper ME, Campbell DJ and Skinner SL. The renin-angiotensin system and the pathogenesis of diabetic microvascular disease: studies in rodent models. In "100 Years of the Renin-Angiotensin System". Pages 112-115. Edited by M.G. Nicholls, H.R. Brunner, H. Ikram, C.S. Sweet & J.Findlay Walker. Hooper House, Oxford U.K.
162. Jandeleit-Dahm K, Cao Z, Cox AJ, Kelly DJ, Gilbert RE and Cooper ME. Role of hyperlipidemia in progressive renal disease: focus on diabetic nephropathy. *Kidney Inter* 56, Suppl 71, S31-36, 1999
163. Campbell DJ, Kelly DJ, Wilkinson-Berka JL, Cooper ME, Skinner SL. Increased bradykinin and 'normal' angiotensin peptide levels in diabetic Sprague Dawley and transgenic (mRen-2)27 rats. *Kidney Inter* 71, 211-221, 1999
164. Gilbert RE, Wu LL, Kelly DJ, Cox A, Berka-Wilkinson JL, Johnston CI, Cooper ME. Pathological expression of renin and angiotensin II in the renal tubule following subtotal nephrectomy: implications for the pathogenesis of tubulointerstitial fibrosis. *Am J Path* 155, 429-440, 1999
165. Cao Z, Dean R, Wu L, Casley D and Cooper ME. Role of angiotensin receptor subtypes in mesenteric vascular proliferation and hypertrophy. *Hypertension* 34, 408-414, 1999
166. Gilbert RE and Cooper ME. The tubulointerstitium in progressive diabetic kidney disease. More than an aftermath of glomerular injury? *Kidney International* 1999, 56:1627-1637
167. Cooper ME and Gilbert RE. Pathogenesis, prevention and treatment of diabetic nephropathy. In: "Comprehensive Clinical Nephrology". Eds. Feehally J and Johnson R. Harcourt Publishers Ltd, London UK. 1999
168. Cooper ME, Vranes D, Youssef S, Stacker SA, Cox AJ, Rizkalla B, Casley DJ, Kelly DJ, Bach LA and Gilbert RE. Increased Renal Expression of VEGF and its Receptor VEGFR-2 in Experimental Diabetes. *Diabetes* 48, 2229-39, 1999
169. Boner G and Cooper ME. Diabetic Nephropathy (Review). *Diabetes Technology & Therapeutics* 1, 489-496, 1999
170. Chattington P and Cooper ME. New targets for the prevention and treatment of diabetic nephropathy. In: *Diabetes: Current Perspectives*. Ed: DJ Betteridge. Martin Dunitz Publishers. London 2000, pp165-178.
171. Cooper ME. Mechanisms of diabetic complications (nephropathy) as related to perspectives of treatment. In: *New Concept in Diabetes and its Treatment*. Vol 133, pp125-134, Eds: Belfiore F and Mogensen CE. Karger AG, Basel 2000 Switzerland.
172. Kelly DJ, Skinner SL, Gilbert RE, Cox AJ, Cooper ME and Wilkinson-Berka JL. Effects of endothelin or angiotensin II receptor blockade on diabetes in the transgenic (mRen-2)27 rat. *Kidney International* 57, 1882-1894, 2000.
173. Cooper ME, Jerums G and Chattington PD. Treatment of hypertension in diabetes. *Saudi J Kidney Diseases and Transplantation* 10, 325-330, 1999
174. Bach LA, Dean R, Youssef S and Cooper ME. Aminoguanidine ameliorates changes in the IGF system in experimental diabetic nephropathy. *Nephrol Dial Transplant* 15, 347-354, 2000

175. Gilbert RE, Cox AJ, Kelly DJ, Wilkinson-Berka JL, Sage EH, Jerums G, Cooper ME: Localization of secreted protein acidic and rich in cysteine (SPARC) expression in the rat eye. *Connective Tissue Research* 1999, 40:295-303
176. Cooper ME. Diabetes and hypertension. *Dialogue* 4thQ, 11-16, 1999
177. Gilbert RE, Rumble JR, Cao Z, Cox AJ, van Eeden P, Allen TJ, Kelly DJ, Cooper ME: Endothelin receptor antagonism ameliorates mast cell infiltration, vascular hypertrophy and epidermal growth factor expression in experimental diabetes. *Circulation Research* 2000, 86:158-165
178. Cooper ME and Jerums G. Role of advanced glycation in diabetic nephropathy. In "The kidney and hypertension in diabetes mellitus". 5th Edition. Ed. CE Mogensen, Kluwer Academi Publishers, Norwell, Mass USA pp247-253, 2000.
179. Cooper ME, McNally PJ and Boner G. Antihypertensive treatment in NIDDM, with special reference to abnormal albuminuria. In "The kidney and hypertension in diabetes mellitus". 5th Edition. Ed. CE Mogensen, Kluwer Academi Publishers, Norwell, Mass USA in press, 2000.
180. Jandeleit-Dahm K, Allen TJ, Youssef S, Gilbert RE, Cooper ME. Is there a role for endothelin antagonists in diabetic renal disease? *Diabetes, Obesity and Metabolism*; 1, 1-10, 1999
181. Jandeleit-Dahm K, Rumble JR, Cox AJ, Kelly D, Cooper ME, Gilbert RE. SPARC Gene Expression Is Increased in Diabetes-Related Mesenteric Vascular Hypertrophy. *Microvascular Research*; 59: 61-71, 2000.
182. Moravski CJ, Wilkinson-Berka JL, Kelly DJ, Gilbert RE, Skinner SL and Cooper ME. Angiotensin II antagonism in diabetic retinopathy. *Receptors in Cardiovascular disease*. 6(4) 1-4, 2000
183. Kelly DJ, Allen TJ and Cooper ME. Experimental diabetic nephropathy: Is it relevant to the human disease. *Nephrology* 5, 177-185, 2000
184. Cao Z, Cooper ME, Wu LL, Cox AJ, Jandeleit-Dahm K, Kelly DJ and Gilbert RE. Blockade of the renin angiotensin and endothelin systems on progressive renal injury. *Hypertension* 36 561-568, 2000.
185. Cooper ME, Thallas V, Forbes J, Scalbert E, Sastra S, Darby I and Soulis T. The cross-link breaker, N-phenacylthiazolium bromide prevents vascular advanced glycation end-product accumulation. *Diabetologia* 43, 660-664, 2000
186. Wookey P and Cooper M. Amylin and hypertension: the status of the current debate. *Diabetologia* 43, 263, 2000
187. Yu XQ, Wu LL, Huang XR, Yang N, Gilbert RE, Cooper ME, Johnson RJ, Lai KN, Hui Y, Lan HY. Osteopontin Expression in Progressive Renal Injury in Remnant Kidney: Role of Angiotensin II. *Kidney Inter* 58, 1469-1480, 2000
188. Cooper ME and Johnston CI. Optimizing treatment of hypertension in patients with diabetes *JAMA* 283, 3177-79, 2000
189. Cao Z, Kelly DJ, Cox A, Casley D, Forbes JM, Martinello P, Dean R, Gilbert RE and Cooper ME. The angiotensin type 2 receptor is expressed in the adult rat kidney and promotes cellular proliferation and apoptosis. *Kidney Inter* 58, 2437-2451, 2000
190. Mogensen CE, Neldam S, Tikkanen I, Oren S, Viskoper R, Watts RW and Cooper ME for the CALM study group. Randomised controlled trial of dual blockade of the renin-angiotensin system in hypertensive, microalbuminuric, non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. *Brit Med J* 321, 1440-1444, 2000

191. Gilbert RE, Kelly DJ, Cox AJ, Berka-Wilkinson JL, Rumble JR, Osicka T, Panagiotopoulos S, Lee V, Hendrich EC, Jerums G and Cooper ME. Angiotensin Converting enzyme inhibition ameliorates retinal overexpression of vascular endothelial growth factor and hyperpermeability in experimental diabetes. *Diabetologia* 43, 1360-1367, 2000
192. Moravski CJ, Kelly DJ, Cooper ME, Bertram JF, Shahinfar S, Cox A, Gilbert RE, Skinner SL, Wilkinson-Berka JL. Retinal neovascularization is prevented by blockade of the renin-angiotensin system. *Hypertension* 36, 1099-1104, 2000
193. Forbes JM, Soulis T, Thallas V, Panagiotopoulos S, Long DM, Vasani S, Wagle D, Jerums G, Cooper ME. Renoprotective effects of a novel inhibitor of advanced glycation. *Diabetologia* 44, 108-114, 2001.
194. Bonnet F, Cooper ME. Potential influence of lipids in diabetic nephropathy: insights from experimental data and clinical studies. *Diabetes Metab* 26, 254-264, 2000
195. Jandeleit-Dahm K, Hannan KM, Farrelly CA, Allen TJ, Rumble JR, Gilbert RE, Cooper ME and Little PJ. Diabetes induced vascular hypertrophy is accompanied by activation of Na⁺/H⁺ exchange and prevented Na⁺/H⁺ exchange inhibition. *Circ Res* 87, 1133-1140, 2000
196. Cooper ME, Bonnet F, Oldfield M and Jandeleit-Dahm K. Mechanisms of diabetic vasculopathy: an overview. *Am J Hypertens* 14, 475-486, 2001
197. Cooper ME, Webb RL and de Gasparo M. Angiotensin receptor blockers and the kidney; possible advantages over ACE inhibition? *Cardiovascular Drug Reviews*, 1, 75-86, 2001
198. Jerums G, Allen TJ, Campbell DJ, Cooper ME, Gilbert RE, Hammond JJ, Raffaele J, Tsalamandris C on behalf of the Melbourne Diabetic Nephropathy Study Group. Long-term comparison between perindopril and nifedipine in normotensive patients with Type 1 diabetes and microalbuminuria. *Am J Kidney Disease* 37:890-899, 2001
199. Cooper ME. Long-term renoprotective effect of nisoldipine and lisinopril in type 1 diabetic patients with diabetic nephropathy - Response to Tarnow et al (Editorial). *Diabetes Care* 23, 1723-4, 2000
200. Cooper ME and Bonnet F. Renoprotective effects of ACE inhibition in type 2 diabetic patients. *ACE Newsletter* 53 2-4, 2000
201. Johnston CI, Cooper ME, Taylor AJ and Shaw JA. Defining moments in medicine – Internal Medicine. *Med J Aust* 174, 9-11, 2001
202. Gilbert RE, Kelly DJ, McKay T, Chadban S, Hill PA, Cooper ME, Atkins RC, Nikolic-Paterson DJ. PDGF signal transduction inhibition ameliorates experimental mesangial proliferative glomerulonephritis. *Kidney Inter* 59, 1324-32, 2001
203. Bonnet F, Cooper ME, Carey RM, Casley D, Cao Z. Vascular expression of angiotensin type 2 receptor in the adult rat: influence of angiotensin II infusion. *J Hypertens* 19, 1075-81, 2001
204. Cao Z, Bonnet F, Davis B, Cox AJ, Allen T, Cooper ME. Additive hypotensive and antialbuminuric effects of angiotensin converting enzyme inhibition and angiotensin receptor antagonism in diabetic spontaneously hypertensive rat. *Clin Sci* 100, 591-99, 2001
205. Wilkinson-Berka JL, Gibbs N, Skinner SL, Cooper ME, DJ Kelly. Renoprotective and anti-hypertensive effects of combined valsartan and perindopril in progressive diabetic nephropathy in the transgenic (mRen-2)²⁷ rat. *Nephrology, Dialysis, Transplantation*, 16:1343-9, 2001

206. Bonnet F, Cao Z, Cooper M: Apoptosis and angiotensin II; yet another renal regulatory system. *Exp Nephrol*, 9, 295-300, 2001
207. Jandeleit-Dahm K, Wu LL, Johnson RJ, Cox AJ, Kelly DJ, Cooper ME, Gilbert RE. ACE inhibition attenuates renal PDGF gene expression and cell proliferation in subtotal nephrectomy. *Nephrology* 6, 290-7, 2001
208. Brenner BM, Cooper ME, de Zeeuw D, Grunfeld J-P, Keane WF, Kurokawa K, McGill JB, Mitch WE, Parving HH, Remuzzi G, Ribeiro AB, Schluchter MD, Snively D, Zhang Z, Simpson R, Ramjit D, Shahinfar S, for the RENAAL study investigators. The losartan renal protection study – rationale, study design and baseline characteristics of RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan). *JRAAS* 1, 328-335, 2000.
209. Kelly DJ, Gilbert RE, Cox AJ, Soulis T, Jerums G, Cooper ME. Aminoguanidine ameliorates overexpression of prosclerotic growth factors and collagen deposition in experimental diabetic nephropathy. *J Am Soc Nephrol* 10, 2098-2107, 2001.
210. Cao Z, Burrell LM, Tikkanen I, Bonnet F, Cooper ME, Gilbert R. Vasopeptidase inhibition attenuates the progression of renal injury in subtotal nephrectomised rats. *Kidney Int* 60:715-21, 2001
211. Mifsud SA, Allen TJ, Bertram JF, Hulthen UL, Kelly DJ, ME Cooper ME, Wilkinson-Berka JL, Gilbert RE. Podocyte foot process broadening in experimental diabetic nephropathy: amelioration with renin-angiotensin blockade. *Diabetologia* 44, 878-882, 2001
212. Bonnet F, Cooper ME, Kawachi H, Allen TJ, Boner G and Cao Z. Irbesartan normalises the deficiency in glomerular nephrin expression in a model of diabetes and hypertension. *Diabetologia* 44, 874-877, 2001
213. Chalmers J, Cooper M, Ferrannini E, Glasziou P, Grobbee D, Hamet P, Harrap S, Liu L, MacMahon S, Mancia G, Marre M, Matthews D, Mogensen C, Neal B, Pan C Y, Poulter N, Rodgers A, Williams B, Woodward M: ADVANCE Management Committee. ADVANCE: Action in Diabetes and Vascular Disease - Preterax and Diamicron MR Controlled Evaluation. Study design and rationale. *Diabetologia* 44, 118-20, 2001.
214. Paizis G, Gilbert RE, Cooper ME, Murthi P, Schembri JM, Wu LL, Rumble JR, Kelly DJ, Tikellis C, Cox A, Smallwood RA, Angus PW. Effect of angiotensin II type 1 receptor blockade on experimental hepatic fibrogenesis. *J Hepatology*. 35, 376-385, 2001
215. Cooper ME. Interaction of metabolic and haemodynamic factors in mediating experimental diabetic nephropathy. *Diabetologia* 44, 1957-1972, 2001
216. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving H-H, Remuzzi G, Snappin SM, Zhang Z, Shahinfar S for the RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes and mortality in patients with type 2 diabetes and nephropathy: Results of the *Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan* (RENAAL) study. *N Engl J Med* 345, 861-869, 2001
217. Yu D-Y, Cringle SJ, Su E-N, Yu PK, Jerums G and Cooper ME. Pathogenesis and intervention strategies in diabetic retinopathy. *Clin Exp Ophthalmol* 29, 164-166, 2001
218. Cooper ME and Chattington P. Chapter 8.4 “Hypertension and diabetes mellitus” in *Manual of Hypertension*. Eds. Mancia et al. Harcourt Publishers Ltd London, UK pp565-577, 2002

219. Cooper ME. ACE and Diabetes. In: ACE inhibitors. Eds: D'Orléans-Juste P and Plante GE. pp. 177-184. Milestones in Drug Therapy Series. Birkhauser Verlag, Basel, Switzerland 2001
220. Jerums G, Cooper ME, Gilbert RE and Atkins RC. Renal protection by angiotensin II receptor antagonists in patients with type 2 diabetes. *Medical Journal of Australia* 175, 397-399, 2001.
221. Cao Z and Cooper ME. Role of angiotensin II in tubulointerstitial injury. *Seminars in Nephrology* 21, 554-562, 2001
222. Mifsud SA, Skinner SL, Cooper ME, Kelly DJ and Wilkinson-Berka J. Effects of low dose and early versus late perindopril on the progression of severe diabetic nephropathy in the (mREN-2) 27 rat. *J Am Soc Nephrol* 13 684-692, 2002
223. Oldfield MD, Bach LA, Forbes JM, Nikolic-Paterson D, McRobert A, Thallas V, Atkins RC, Osicka T, Jerums G and Cooper ME. Advanced Glycation Endproducts cause epithelial-myofibroblast transdifferentiation via the receptor for advanced glycation end products (RAGE). *J Clin Invest* 108, 1853-1863, 2001
224. Cooper M and Epstein M. Evolving role of angiotensin II receptor antagonists in diabetes mellitus in: *Angiotensin II receptor antagonists*. Eds: Epstein M and Brunner pp317-328. Hanley & Belfus Philadelphia USA 2001
225. Oldfield MD and Cooper ME. How is diabetic microvascular disease best prevented and treated? In *Diabetes Annual 2002*. Ed: Barnett AH. Martin Dunitz Ltd. London, UK pp61-86.
226. Tikkanen I, Tikkanen T, Cao Z, Allen T, Davis B, Lassila M, Casley D, Johnston C, Burrell L, Cooper M. Combined inhibition of neutral endopeptidase with angiotensin converting enzyme or endothelin converting enzyme in experimental diabetes. *J Hypertens* 20, 707-714, 2002
227. Jandeleit-Dahm KA and Cooper ME. Hypertension and diabetes. *Curr Opinion Nephrol Hypertension* 11, 221-228, 2002
228. Oldfield MD and Cooper ME. The biochemistry and pathophysiology of renal lesions in type 2 diabetes. In *Diabetic nephropathy in type 2 diabetes*. Ed: Mogensen CE. Science Press Ltd. London, UK pp41-56, 2002.
229. Houlihan CA, Allen TJ, Baxter AL, Panangiotopoulos S, Casley DJ, Cooper ME, Jerums G. A low sodium diet potentiates the effects of losartan in Type 2 diabetes. *Diabetes Care* 25, 663-671, 2002
230. Forbes JM, Bonnet F, Russo LM, Burns WC, Cao Z, Candido R, Kawachi H, Allen TJ, Cooper ME, Jerums G, Osicka TM. Modulation of nephrin in the diabetic kidney: association with systemic hypertension and increasing albuminuria. *J Hypertens* 20, 985-992, 2002
231. Kanellis J, Paizis K, Cox AJ, Stacker SA, Gilbert RE, Cooper ME, Power DA. Renal ischemia-reperfusion increases endothelial VEGFR-2 without increasing VEGF or VEGFR-1 expression. *Kidney International* 61, 1696-1706, 2002.
232. Epstein M and Cooper ME. Diabetic nephropathy: Focus on ACE inhibition and calcium channel blockade. in: *Calcium Antagonists in Clinical Medicine*. Ed. Epstein M. 3rd Edition. Hanley & Belfus Inc. Philadelphia USA pp383-410 2002.
233. Cooper ME and Gilbert RE. Pathogenesis, prevention and treatment of diabetic nephropathy. In: "Comprehensive Clinical Nephrology" 2nd edition. Eds. Johnson RJ and Feehally J. Mosby, Elsevier Inc Burlington MA, USA 2003. pp439-450,

234. Kelly DJ, Cox AJ, Tolcos M, Cooper ME, Wilkinson-Berka JL, Gilbert RE. Attenuation of tubular apoptosis by blockade of the renin-angiotensin system in diabetic Ren-2 rats. *Kidney Inter* 61, 31-39, 2002.
235. Oldfield MD and Cooper ME. Growth factors in diabetic microangiopathy. *Modern Diabetes Management*. 3 (1) 10-14, 2002
236. Candido R, Fabris B and Cooper ME. Treatment for diabetic nephropathy – a review of the recent patent literature. *Investigational Drugs Journal IDrugs* 5, 237-265, 2002
237. Bonnet F, Tikellis C, Kawachi H, Burns WC, Wookey PJ, Cao Z and Cooper ME. Nephron expression in the post-natal developing kidney in normotensive and hypertensive rats. *Clin Exp Hypertension* 24, 371-381, 2002
238. Cao Z, Bonnet F, Candido R, Nesteroff SP, Burns WC, Kawachi H, Shimizu F, Carey RM, de Gasparo M and Cooper ME. Angiotensin type 2 receptor antagonism confers renal protection in a rat model of progressive renal injury. *J Am Soc Nephrol*, 13, 1773-1787, 2002
239. Candido R, Jandeleit-Dahm KAM, Cao Z, Nesteroff SP, Burns WC, Twigg, SM, Dilley RJ, Cooper ME, Allen TJ. Prevention of accelerated atherosclerosis by ACE inhibition in diabetic apolipoprotein e-deficient mice. *Circulation* 106, 246-253, 2002
240. Bonnet F, Candido R, Carey RM, Casley D, Russo LM, Osicka TM, Cooper ME and Cao Z. Renal expression of angiotensin receptors in long term diabetes and the effects of angiotensin type 1 receptor blockade. *J Hypertens* 20: 1615-1624, 2002
241. Parving, HH, Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Remuzzi G, Snapinn SM, Zhang Z and Shahinfar S. Effect of losartan on renal and cardiovascular complications of patients with type 2 diabetes and nephropathy. *Ugeskr Laeger* 163, 5514-9, 2001
242. Boner G, Cao Z, and Cooper ME. Combination antihypertensive therapy in the treatment of diabetic nephropathy. *Diabetes Technology & Therapeutics*, 2002. 4, 313-321, 2002
243. Houlihan CA, Akdeniz A, Tsalamandris C, Cooper ME, Jerums G, Gilbert RE. Urinary transforming growth factor-beta excretion in patients with hypertension, type 2 diabetes, and elevated albumin excretion rate: effects of angiotensin receptor blockade and sodium restriction. *Diabetes Care* 25, 1072-7, 2002
244. Tolcos M, Tikellis C, Rees S, Cooper M, Wookey P. Ontogeny of calcitonin receptor mRNA and protein in the developing central nervous system of the rat. *J Comp Neurol*. 456, 29-38, 2003
245. Wookey PJ, Xuereb L, Tikellis C, Cooper ME. The roles of amylin in the periphery: a review. *The Scientific World*, 3, 163-75, 2003.
246. Tikellis C, Xuereb L, Casley D, Brasier G, Cooper ME, Wookey PJ. Calcitonin receptor isoforms expressed in the developing rat kidney. *Kidney Int* 63, 416-426, 2003.
247. Thomas MC and Cooper ME. Turning up the heat: HSP, hypertension and cardiovascular risk: Editorial Comment. *J Hypertension* 20, 171314, 2002
248. Forbes JM, Cooper ME, Thallas V, Burns WC, Brammar GC, Lee F, Grant S, Burrell L, Jerums G, Osicka TM. Reduction of the accumulation of advanced glycation end products by angiotensin converting enzyme inhibition in experimental diabetic nephropathy. *Diabetes* 51, 3274-3282, 2002.

249. Wilkinson-Berka JL, Kelly DJ, Koerner SM, Jaworski K, Davis B, Thallas V, Cooper ME. ALT-946 and aminoguanidine, inhibitors of advanced glycation, improve severe nephropathy in the diabetic transgenic (mren-2)27 rat. *Diabetes* 51, 3283-3289, 2002
250. Paizis G, Cooper ME, Schembri J, Tikellis C, Burrell LM and Angus PW. Upregulation of components of the renin-angiotensin system in the bile duct ligated rat liver. *Gastroenterology* 123, 1667-1676, 2002
251. Stitt A, Jenkins A and Cooper ME. AGEs and the complications of diabetes. *Expert Opinion Investig Drugs* 11, 1205-1223, 2002
252. Davis BJ, Cao Z, de Gasparo M, Kawachi H, Cooper ME and Allen TJ. Disparate effects of angiotensin II antagonists and calcium channel blockers on albuminuria in experimental diabetes and hypertension: Potential role of nephrin. *J Hypertens* 21: 209-216, 2003
253. Twigg SM, Cao Z, McLennan SV, Burns WC, Brammar G, Forbes JM and Cooper ME. Renal Connective Tissue Growth Factor Induction in Experimental Diabetes is prevented by Aminoguanidine. *Endocrinology* 143, 4907-15, 2002
254. Moravski C, Skinner SL, Stubbs AJ, Sarlos S, Kelly DJ, Cooper ME, Gilbert RE, Wilkinson-Berka JL. The renin-angiotensin system influences ocular endothelial cell proliferation in diabetes: transgenic and interventional studies. *Am J Pathol* 162, 151-160, 2003
255. Rice E, Tesch G, Cao Z, Cooper ME, Metz C, Atkins R, Nikolic-Paterson D: Induction of MIF synthesis and secretion by tubular epithelial cells-a novel action of angiotensin II. *Kidney Int* 63, 1265-1275, 2003
256. Bui BV, Armitage JA, Tolcos M, Cooper ME, Vingrys AJ. ACE inhibition salvages the visual loss caused by diabetes. *Diabetologia* 46, 401-408, 2003
257. Cooper ME, Mundel P and Boner G. Role of nephrin in renal disease including diabetic nephropathy. *Semin Nephrol* 22, 393-398, 2002
258. Thomas MC, Tikellis C, Burns WC, Forbes JM, Cao Z, Thallas V, Osicka TM, Russo LM, Jerums G, Ghabrial H, Cooper ME, Kantharidis P. Reduced tubular cation transport in diabetes: prevented by ACE inhibition. *Kidney International* 63, 2152-2161, 2003
259. Thomas MC, Cooper ME, Shahinfar S, Brenner BM. Dialysis delayed is death prevented. A clinical perspective on the RENAAL study. *Kidney International* 63, 1577-79, 2003
260. Lassila M, Davis BJ, Allen TJ, Burrell LM, Cooper ME, Cao Z. Cardiovascular hypertrophy in diabetic spontaneously hypertensive rats: optimising blockade of the renin angiotensin system. *Clin Sci* 104, 341-347, 2003
261. Tikellis C, Johnston CI, Forbes JM, Burns WC, Burrell LM, Risvanis J, Cooper ME. Characterisation of renal Angiotensin Converting Enzyme 2 in Diabetic Nephropathy. *Hypertension* 41, 392-7, 2003
262. Davis BJ, Burns WC, Kubota E, Burrell LM, Johnston CI, Cooper ME and Allen TJ. Renoprotective effects of dual ACE/NEP inhibition in an experimental model of diabetic nephropathy. *Diabetologia* 46, 961-71, 2003
263. Cooper ME and Thomas MC. Interactions between growth factors in the kidney: Implications for progressive renal injury. *Kidney Inter* 63, 1584-1585, 2003
264. Oldfield MD and Cooper ME. Oxidative stress and glycation: mechanisms and prevention in diabetes. In: *Diabetes From Research to Diagnosis and Treatment*. Eds. Raz I, Skyler JS and Shafir E. Martin Dunitz Ltd. London, UK pp 421-438.

265. Cooper ME. The Prevalence of Hypertension in Patients with Diabetes. Eds. Lippincott Williams & Wilkins UK in press, 2003
266. Candido R, Forbes JM, Thomas MC, Thallas V, Dean RG, Burns WC, Tikellis C, Ritchie RH, Twigg SM, Cooper ME, Burrell LM. Breaker of advanced glycation end products attenuates diabetes-induced myocardial structural changes. *Circulation Research* 92, 785-792, 2003
267. Li JH, Huang XR, Zhu H-J, Oldfield M, Cooper M, Truong LD, Johnson RJ, and Lan HY. Advanced Glycation End Products Activate smad Signaling via TGF- β Dependent and Independent Mechanisms: Implications for Diabetic Renal and Vascular Disease. *FASEB J* 18, 176-178, 2004
268. Calkin AC, Thomas MC, Cooper ME. MK-767, a PPAR alpha and gamma antagonist. *Current Opinion in Investigational Drugs* 4, 444-448, 2003
269. McRobert EA, Gallicchio MA, Jerums G, Cooper ME, Bach LA. The amino terminal domains of ERM proteins bind advanced glycation endproducts: an interaction that may play a role in the development of diabetic complications. *J Biol Chem* 278, 25783-25789, 2003
270. Forbes JM, Thallas V, Thomas MC, Founds HW, Burns WC, Jerums G and Cooper ME. The breakdown of pre-existing advanced glycation end products is associated with reduced renal fibrosis in experimental diabetes. *FASEB J*, 17, 1762-4, 2003
271. Sarlos S, Rizkalla B, Moravski CJ, Cao Z, Cooper ME and Wilkinson-Berka JL. Retinal Angiogenesis is Mediated by an Interaction between the Angiotensin Type 2 Receptor, VEGF and Angiopoietin. *Am J Path* 163, 879-87, 2003
272. Forbes JM, Cooper ME, Oldfield MD and Thomas MC. Role of advanced glycation end products in diabetic nephropathy. *JASN* 8, S254-258, 2003
273. Boner G, Cox AJ, Kelly DJ, Tobar A, Bernheim J, Langham RG, Cooper ME, Gilbert RE. Does vascular endothelial growth factor (VEGF) play a role in the pathogenesis of minimal change disease? *Nephrol Dial Transpl* 18, 2293-99, 2003
274. Gilbert RE and Cooper ME. The pathogenesis of diabetic nephropathy. In: *Diabetes and Hypertension*. Ed. B Williams. Martin Dunitz Publishers London, UK pp191-202, 2003
275. Cooper ME. The clinical implications and management of microalbuminuria and proteinuria in type II diabetic subjects. In: *Diabetes and Hypertension*. Ed. B Williams. Martin Dunitz Publishers London, UK pp219-236, 2003
276. MacIsaac RJ and Cooper ME. Microalbuminuria and diabetic cardiovascular disease. *Current Atherosclerosis Reports* 5, 350-357, 2003
277. Qin J, Zhang Z, Liu J, Sun L, Hu L, Cooper ME and Cao Z. Effects of the combination of an angiotensin II antagonist with a HMG-CoA reductase inhibitor in experimental diabetes. *Kidney International* 64: 565-571, 2003.
278. Rizkalla B, Cao Z, Forbes JM and Cooper ME. Increased renal VEGF and angiopoietins by angiotensin II infusion is mediated by both AT₁ and AT₂ receptors. *J Am Soc Nephrol* 14, 3061-71, 2003
279. Davis B, Forbes JM, Thomas MC, Jerums G, Burns WC, Kawachi H, Allen TJ and Cooper ME. Superior renoprotective effects of combination therapy with ACE and AGE inhibition in a hypertensive model of experimental diabetes. *Diabetologia* 47, 89-97, 2004
280. Candido R, Srivastava P, Cooper ME and Burrell LM. Diabetes mellitus: a cardiovascular disease. *Current Opinion in Investigational Drugs* 4, 1088-94, 2003

281. Brasier G, Tikellis C, Xuereb L, Craigie J, Casley D, Kovacs CS, Fudge NJ, Kalnins R, Cooper ME, Wookey PJ. Novel hexad repeats conserved in a putative transporter with restricted expression in cell types associated with growth, calcium exchange and homeostasis. *Experimental Cell Research* 293, 31-42, 2004.
282. Bonnet F, Cao Z, Cooper ME, Cox A, Kelly DJ and Gilbert, R. Tranilast attenuates vascular hypertrophy, matrix accumulation and growth factor overexpression in experimental diabetes. *Diabetes Metab* 29, 386-92, 2003.
283. Levidiotis V, Freeman C, Tikellis C, Cooper ME and Power DA. Heparanase is involved in the pathogenesis of proteinuria as a result of glomerulonephritis. *J Am Soc Nephrol* 15, 68-78, 2004
284. Mogensen CE and Cooper ME. Diabetic renal disease: from recent studies to improved clinical practice. *Diabetic Medicine* 21, 4-17, 2004
285. Tikellis C, Cooper ME, Twigg SM and Tolcos M. Connective Tissue Growth Factor is Up-regulated in the Diabetic Retina: Amelioration by ACE Inhibition. *Endocrinology* 145, 860-66, 2004
286. Kanellis J, Levidiotis V, Khong T, Cox AJ, Stacker SA, Gilbert RE, Cooper ME and Power DA. A study of VEGF and its receptors in two rat models of proteinuria. *Nephron Physiol* 96, P26-36, 2004
287. Jerums G, Panagiotopoulos S, Forbes J, Osicka T and Cooper ME. Evolving concepts in advanced glycation, diabetic nephropathy and diabetic vascular disease. *Archives of Biochemistry and Biophysics* 419, 55-62, 2003
288. Candido R, Allen TJ, Lassila M, Cao Z, Thallas V, Cooper ME and Jandeleit-Dahm KA. Irbesartan but not amlodipine suppresses diabetes-associated atherosclerosis. *Circulation* 109, 1536-54, 2004
289. MacIsaac RJ, Jerums G and Cooper ME. New insights into the significance of microalbuminuria. *Current Opinion Nephrol Hypertension* 13, 83-91, 2004
290. Tikellis C, Wookey PJ, Candido R, Andrikopoulos S, Thomas MC and Cooper ME. Improved islet morphology following blockade of the renin angiotensin system in the ZDF rat. *Diabetes* 53, 989-997, 2004
291. Zhang X, Lassila M, Cooper ME, Cao Z. Retinal Expression of Vascular Endothelial Growth Factor Is Mediated by Angiotensin Type 1 and Type 2 Receptors. *Hypertension* 43, 276-281, 2004
292. Candido R, Burrell LM, Jandeleit-Dahm KA and Cooper ME. Vasoactive peptides and the kidney. Chapter 16, pp. 663-726 in: Brenner & Rector's *The Kidney*. Seventh Edition. Ed: Brenner BM. Saunders, Elsevier Inc. Philadelphia, PA, USA 2004.
293. Li HJ, Wang WS, Huang XR, Oldfield M, Schmidt A, Cooper ME, Lan HY. Advanced glycation end products induce tubular epithelial-myofibroblast transition through the RAGE-ERK1/2 MAP kinase signaling pathway. *Am J Pathol* 164, 1389-1397, 2004
294. Cooper M and Boner G. Horizons: Dual blockade of the renin-angiotensin system in diabetic nephropathy. *Diabetic Medicine* 21, 15-18, 2004
295. Lassila M, Allen TJ, Cao Z, Thallas V, Jandeleit-Dahm KA, Candido R, Cooper ME. Imatinib attenuates diabetes-associated atherosclerosis. *Arteriosclerosis Thrombosis Vascular Biology* 24, 935-42, 2004
296. Allen TJ, Cooper ME and Lan HY. Use of genetic mouse models in the study of diabetic nephropathy. *Current Atherosclerosis Reports* 6, 197-202, 2004

297. Wigg SJ, Tare M, Forbes J, Cooper ME, Thomas MC, Coleman HA, Parkington HC, O'Brien RC. Early vitamin E supplementation attenuates diabetes-associated vascular dysfunction and the rise in protein kinase C in mesenteric artery and ameliorates wall stiffness in femoral artery in rats. *Diabetologia* 43, 1038-46, 2004
298. Burrell LM, Johnston CI, Tikellis C and Cooper ME. ACE2, a new regulator of the renin angiotensin system. *Trends in Endocrinology Metabolism* 15, 166-169, 2004
299. De Zeeuw D, Remuzzi G, Parving H-H, Keane WF, Zhang Z, Shahinfar S, Snappin S, Cooper ME, Mitch WE and Brenner BM. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy; lessons from RENAAL. *Kidney Inter* 65, 2309-2320, 2004
300. de Zeeuw D, Remuzzi G, Parving H-H, Keane WF, Zhang Z, Shahinfar S, Snappin S, Cooper ME, Mitch WE and Brenner BM. Proteinuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. *Circulation* 110, 921-927, 2004
301. Thomas M, Tsalamandris C, MacIsaac R, Medley T, Kingwell B, Cooper ME and Jerums G. Low molecular weight AGEs are associated with GFR and anemia in patients with type 2 diabetes. *Kidney Inter* 66, 1167-1172, 2004
302. Forbes JM, Thallas-Bonke V, Cooper ME, Thomas MC. Advanced glycation: How are we progressing to combat this web of sugar anomalies in diabetic nephropathy? *Curr Pharmaceut Design*, 10, 3361-72, 2004.
303. Mifsud SA, Burrell LM, Kubota E, Jaworski K, Cooper ME, Wilkinson-Berka JL: Cardiorenal protective effects of vasopeptidase inhibition with omapatrilat in hypertensive transgenic (mREN-2)27 rats. *Clin Exp Hypertens* 26, 69-80, 2004
304. Ma G, Allen TJ, Cooper ME and Cao Z. Calcium channel blockers, either amlodipine or mibefradil, ameliorated renal injury in experimental diabetes. *Kidney International*, 66, 1090-98, 2004.
305. Boner G, McNally PJ and Cooper ME. Antihypertensive treatment in NIDDM, with special reference to abnormal albuminuria. In "The kidney and hypertension in diabetes mellitus". 6th Edition. Ed. CE Mogensen, Taylor & Francis Publishers, London, UK 579-610, 2004.
306. Thomas MC, Cooper ME and Jerums G. Advanced glycation end-products and diabetic renal disease. In "The kidney and hypertension in diabetes mellitus". 6th Edition. Ed. CE Mogensen, Taylor & Francis Publishers, London, UK 303-322, 2004.
307. Forbes J, Yee LTL, Thallas V, Lassila M, Candido R, Jandeleit-Dahm KA, Thomas MC, Burns WC, Deemer EK, Thorpe SM, Cooper ME, Allen TJ. Advanced Glycation End Product Interventions Reduce Diabetes Accelerated Atherosclerosis. *Diabetes* 53, 1813-23, 2004
308. Jerums G, Allen TJ, Campbell DJ, Cooper ME, Gilbert RE, Hammond JJ, O'Brien RC, Raffaele J, Tsalamandris C on behalf of the Diabetic Nephropathy Study Group. Long-term renoprotection by perindopril or nifedipine in non-hypertensive patients with type 2 diabetes and microalbuminuria. *Diabetic Medicine* 21, 1192-9, 2004
309. Tikellis C, Johnston CI, Forbes JM, Burns WC, Thomas MC, Lew RA, Yarski M, Smith AI, Cooper ME. Identification of Angiotensin Converting Enzyme 2 in the Rodent Retina. *Current Eye Research* 29, 419-27, 2004
310. Thomas MC and Cooper ME. Blockade of the RAS: better late than never. *Am J Kidney Disease* 43, 1113-1115, 2004

311. Twigg SM and Cooper ME. The time to target Connective Tissue Growth Factor in diabetic complications is nigh. *Diabetologia* 43, 965-8, 2004
312. Chan JC, Wat NM, So WY, Lam KS, Chua CT, Wong KS, Morad Z, Dickson TZ, Hille D, Zhang Z, Cooper ME, Shahinfar S, Brenner BM, Kurokawa K. Renin angiotensin aldosterone system blockade and renal disease in patients with type 2 diabetes: an Asian perspective from the RENAAL study. *Diabetes Care* 2004; 27:874-879.
313. Lassila M and Cooper ME. Platelet-derived growth factor in experimental diabetic atherosclerosis. <http://www.athero.org/commentaries/comm288.asp>
314. Lee F, Cao Z, Long DM, Panagiotopoulos S, Jerums G, Cooper ME, Forbes JM. Interactions between angiotensin II and nuclear factor kappa B dependent pathways in modulating macrophage infiltration in experimental diabetic nephropathy. *J Am Soc Nephrol*, 15:2139-2151, 2004.
315. Lassila M, Seah KK, Allen TJ, Thallas V, Thomas MC, Candido R, Burns WC, Forbes JM, Calkin AC, Cooper ME, Jandeleit-Dahm K. Accelerated nephropathy in diabetic apolipoprotein E knockout mice: Role of advanced glycation end products. *J Am Soc Nephrol* 15, 2125-38, 2004.
316. Thallas-Bonke V, Lindschau C, Rizkalla B, Bach LA, Boner G, Meier M, Haller H, Cooper ME, Forbes JM. Attenuation of Extracellular Matrix Accumulation in Diabetic Nephropathy by the Advanced Glycation End Product Cross-Link Breaker ALT-711 via a Protein Kinase C- α -Dependent Pathway *Diabetes* 53, 2921-2930, 2004.
317. Rizkalla B, Forbes JM, Cao Z, Boner G and Cooper ME. Temporal renal expression of angiogenic growth factors and their receptors in experimental diabetes: role of the renin-angiotensin system. *J Hypertens* 23, 153-164, 2005
318. Fukami K, Ueda S, Yamagishi S, Kato S, Inagaki Y, Takeuchi M, Motomiya Y, Bucala R, Iida S, Tamaki K, Imaizumi T, Cooper ME, Okuda S. AGEs activate mesangial TGF- β -Smad signaling via an angiotensin II-type I receptor interaction. *Kidney Inter* 66, 2137-47, 2004
319. Forbes JM, Thomas MC, Thorpe SR, Alderson NL and Cooper ME. The effects of valsartan on the accumulation of circulating and renal advanced glycation end products in experimental diabetes. *Kidney Inter* 66 (Suppl 92) S1-3, 2004
320. Thomas MC, Tikellis C, Burns WC, Thallas V, Kantharidis P, Cooper ME, Forbes JM, The role of advanced glycation in reduced organic cation transport associated with experimental diabetes. *J Pharmacol Exp Ther* 311, 456-66, 2004.
321. Lassila M, Cooper ME, Jandeleit-Dahm K. Antiproteinuric Effect of RAS Blockade: New Mechanisms. *Curr Hypertens Rep* 2004; 6:383-392.
322. ADVANCE Collaborative Group. ADVANCE - Action in Diabetes and Vascular Disease: patient recruitment and characteristics of the study population at baseline. *Diabetic Medicine* 22, 882-8, 2005
323. Jandeleit-Dahm, KAM Tikellis C, Reid, CM, Johnston CI, Cooper ME. Why blockade of the renin-angiotensin system reduces the incidence of new-onset diabetes. *J Hypertens* 23:463-473, 2005
324. Parving HH, Mogensen CE, Thomas MC, Brenner BM, Cooper ME. Poor prognosis in proteinuric type 2 diabetic patients with retinopathy: insights from the RENAAL study. *QJM* 98:119-126, 2005

325. Lassila M, Jandeleit-Dahm KAM, Seah KK, Smith CM, Calkin AC, Allen TJ, Cooper ME. Imatinib attenuates diabetic nephropathy in apolipoprotein E-knock out mice. *J Am Soc Nephrol* 16:363-373, 2005
326. Thomas MC, Jerums G, Tsalamandris C, MacIsaac R, Panagiotopoulos S, Cooper ME. Increased tubular organic ion clearance following chronic ACE inhibition in patients with type 1 diabetes. *Kidney International* 67:2494-2499, 2005
327. Cooper ME. Gastrointestinal function in diabetes mellitus. *Intern Med J* 34:659, 2004
328. Cooper ME. The role of the renin-angiotensin-aldosterone system in diabetes and its vascular complications. *Am J Hypertens.* 17, 16S-20S, 2004
329. Allen TJ, Cooper ME, Lan HY. Use of genetic mouse models in the study of diabetic nephropathy. *Curr Diab Report* 4:435-40, 2004.
330. Cooper M, Hammes HP, Horton A. Prediction and early detection of diabetic complications: common pathways and unique needs". Keble College, Oxford August 1-4, 2003. *Diabetologia* 4, R35-46, 2004
331. Thomas MC, Forbes JM, Macisaac R, Jerums G, Cooper ME. Low-Molecular Weight Advanced Glycation End Products: Markers of Tissue AGE Accumulation and More? *Ann N Y Acad Sci.* 1043:644-654, 2005.
332. Burrell LA, Risvanis J, Kubota E, Dean RG, McDonald PS, Lu S, Tikellis S, Grant SL, Lew RA, Smith AI, Cooper ME and Johnston CI. Myocardial infarction increases ACE2 expression in rat and humans. *European Heart Journal* 26:369-375, 2005
333. Cooper ME: Importance of advanced glycation end products in diabetes-associated cardiovascular and renal disease. *Am J Hypertens* 17:S31-38, 2004
334. Mix TC, Brenner RM, Cooper ME, deZeeuw D, de Zeeuw D, Ivanovich P, Levey AS, McGill JB, McMurray JJV, Parfrey PS, Parving H-H, Pereira BJG, Remuzzi G, Singh AK, Solomon SD, Stehman-Breen C, Toto RD and Pfeffer MA. Rationale-Trial to reduce Cardiovascular Events with Aranesp Therapy (TREAT): Evolving the management of cardiovascular risk in patients with chronic kidney disease. *Am Heart J* 149: 408-413, 2005
335. Kooptiwut S, Kebede M, Zraika S, Visinoni S, Aston-Mourney K, Favaloro J, Tikellis C, Thomas MC, Forbes JM, Cooper ME, Dunlop M, Proietto J, Andrikopoulos S. High glucose-induced impairment in insulin secretion is associated with reduction in islet glucokinase in a mouse model of susceptibility to islet dysfunction. *J Mol Endo.* 35, 39-48, 2005
336. Paizis G, Tikellis C, Cooper ME, Schembri JM, Lew RA, Smith AI, Shaw T, Warner FJ, Zulli A, Burrell LM, Angus PW. Chronic liver injury in rat and man upregulates the novel enzyme angiotensin converting enzyme 2. *Gut* 54, 1790-1796, 2005
337. Fukami K, Cooper ME, Forbes JM: Agents in development for the treatment of diabetic nephropathy. *Expert Opin Investig Drugs* 14:279-294, 2005
338. Levidiotis V, Freeman C, Tikellis C, Cooper ME, Power DA: Heparanase inhibition reduces proteinuria in a model of accelerated anti-glomerular basement membrane antibody disease. *Nephrology (Carlton)* 10:167-173, 2005
339. Soldatos G, Cooper ME, Jandeleit-Dahm KA: Advanced-glycation End Products in Insulin-resistant States. *Curr Hypertens Rep* 7:96-102, 2005
340. Thomas MC, Burns WC, Cooper ME: Tubular changes in early diabetic nephropathy. *Adv Chronic Kidney Dis* 12:177-186, 2005

341. Thomas MC, Cooper ME, Tsalamandris C, MacIsaac R, Jerums G: Anemia with impaired erythropoietin response in diabetic patients. *Arch Intern Med* 165:466-469, 2005
342. Boner G, Cooper ME, McCarroll K, Brenner BM, de Zeeuw D, Kowey PR, Shahinfar S, Dickson T, Crow RS, Parving H-H for the RENAAL Investigators. Adverse Effects of Left Ventricular Hypertrophy in the Reduction of Endpoints in NIDDM with Angiotensin II Antagonist Losartan (RENAAL) Study. *Diabetologia* 48, 1980-87, 2005
343. Forbes JM, Thorpe SR, Thallas-Bonke V, Pete J, Thomas MC, Deemer ER, Bassal S, El-Osta A, Long DM, Panagiotopoulos S, Jerums G, Osicka TM, Cooper ME. Modulation of soluble receptor for advanced glycation end products by Angiotensin-converting enzyme-1 inhibition in diabetic nephropathy. *J Am Soc Nephrol.* 16:2363-2372, 2005.
344. Cooper ME, Jandeleit-Dahm KA. Lipids and diabetic renal disease. *Curr Diab Report* 5:445-8, 2005
345. Bach LA, Gallicchio MA, McRobert EA, Tikoo A, Cooper ME. Effects of Advanced Glycation End Products on Ezrin-Dependent Functions in LLC-PK1 Proximal Tubule Cells. *Ann N Y Acad Sci.* 1043:609-616, 2005.
346. Calkin AC, Forbes JM, Smith CM, Lassila M, Cooper ME, Jandeleit-Dahm KA, Allen TJ. Rosiglitazone Attenuates Atherosclerosis in a Model of Insulin Insufficiency Independent of Its Metabolic Effects. *Arterioscler Thromb Vasc Biol.* 25, 1903-1909, 2005
347. Coughlan MT, Cooper ME, Forbes JM. Can advanced glycation end product inhibitors modulate more than one pathway to enhance renoprotection in diabetes? *Ann N Y Acad Sci.* 1043:750-758, 2005.
348. McRobert EA, Tikoo A, Gallicchio MA, Cooper ME, Bach LA. Localization of the ezrin binding epitope for glycated proteins. *Ann N Y Acad Sci.* 1043:617-624, 2005.
349. Dilley RJ, Farrelly CA, Allen TJ, Jandeleit-Dahm K, Cooper ME, Morahan G, Little PJ. Diabetes induces Na/H exchange activity and hypertrophy of rat mesenteric but not basilar arteries. *Diabetes Res Clin Pract.* 70, 201-8, 2005.
350. Thomas MC, Forbes JM, Cooper ME. Interactions between the Renin Angiotensin System and Advanced Glycation in Diabetic Nephropathy. *Ann N Y Acad Sci.* 1043:927, 2005.
351. Thomas MC, Baynes JW, Thorpe SR, Cooper ME. The role of AGEs and AGE inhibitors in diabetic cardiovascular disease. *Curr Drug Targets.* 6:453-474, 2005.
352. Thomas MC and Cooper ME. Facing the music: managing kidney disease in diabetes. *Australasian Journal of general practice.* 5(2), 1-5, 2005
353. Thomas MC, Tikellis C, Burns WM, Bialkowski K, Cao Z, Coughlan MT, Jandeleit-Dahm K, Cooper ME, Forbes JM: Interactions between Renin Angiotensin System and Advanced Glycation in the Kidney. *J Am Soc Nephrol* 16:2976-2984, 2005
354. Tikellis C, Cooper ME, Thomas MC: Role of the renin-angiotensin system in the endocrine pancreas: Implications for the development of diabetes. *Int J Biochem Cell Biol,* 38:737-751, 2006
355. Jandeleit-Dahm K, Lassila M, Davis BJ, Candido R, Johnston CI, Allen TJ, Burrell LM, Cooper ME: Anti-atherosclerotic and renoprotective effects of combined angiotensin-converting enzyme and neutral endopeptidase inhibition in diabetic apolipoprotein E-knockout mice. *J Hypertens* 23:2071-2082, 2005

356. Frojdo S, Sjolind L, Parkkonen M, Makinen VP, Kilpikari R, Pettersson-Fernholm K, Forsblom C, Fagerudd J, Tikellis C, Cooper ME, Wessman M, Groop PH: Polymorphisms in the gene encoding angiotensin I converting enzyme 2 and diabetic nephropathy. *Diabetologia* 48, 2278-81, 2005
357. Cooper ME, Jandeleit-Dahm K, Thomas MC: Targets to retard the progression of diabetic nephropathy. *Kidney Int* 68:1439-1445, 2005
358. Gallicchio MA, McRobert EA, Tikoo A, Cooper ME, Bach LA. Ezrin overexpression inhibits the effects of advanced glycation endproducts on tubulogenesis and migration. *J Am Soc Nephrol* 17:414-421, 2006
359. Thomas MC, Forbes JM, Cooper ME. Advanced glycation end products and diabetic nephropathy. *Am J Ther* 12:562-572, 2005
360. Thomas MC, Rosengard-Barlund M, Mills V, Ronnback M, Thomas S, Forsblom C, Cooper ME, Taskinen MR, Viberti G, Groop PH: Serum lipids and the progression of nephropathy in type 1 diabetes. *Diabetes Care* 29:317-322, 2006
361. Giunti S and Cooper ME. Does the metabolic syndrome make blood pressure control more difficult in diabetes? *J Hypertens* 23, 2155-56, 2005
362. Thomas MC, Cooper ME. Diabetic nephropathy. In: *The Year in Renal Medicine 2005*, Ed. Levy J, Clinical Publishing, Oxford 2005;1:3-22
363. Rossing P, Cooper ME and Parving H-H. Comparison of the effects of vitamins and/or mineral supplementation on glomerular and tubular dysfunction in type 2 diabetes. *Diabetes Care* 29, 747-748, 2006 (Letter)
364. Calkin AC, Cooper ME, Jandeleit-Dahm KA, Allen TJ: Gemfibrozil decreases atherosclerosis in experimental diabetes in association with a reduction in oxidative stress and inflammation. *Diabetologia* 49:766-774, 2006
365. Thomas MC, Cooper ME, Rossing K and Parving H-H. Anaemia in diabetes: is there a rationale to TREAT? *Diabetologia* in press 2006
366. Giunti S, Cooper M: Management strategies for patients with hypertension and diabetes: why combination therapy is critical. *J Clin Hypertens (Greenwich)* 8:108-113, 2006
367. de Zeeuw D, Lewis EJ, Remuzzi G, Brenner BM, Cooper ME: Renoprotective effects of renin-angiotensin-system inhibitors. *Lancet* 367:899-900; 2006